Tysabri labeling changes submitted to help stratify PML risk
Tysabri labeling changes submitted to help stratify PML risk
Biogen Idec and Elan Corporation, plc have announced that the companies have submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) and a Type II Variation to the European Medicines Agency (EMA) to request review and approval to update the respective Tysabri Prescribing Information and Summary of Product Characteristics.
The companies are proposing updated product labeling to include anti-JC Virus antibody status as one potential factor to help stratify the risk of progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection, in the Tysabri-treated population.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1905
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 2461 Views
-
Last post by NHE
-
- 6 Replies
- 6999 Views
-
Last post by ElliotB
-
- 0 Replies
- 1407 Views
-
Last post by NHE
-
- 0 Replies
- 3643 Views
-
Last post by NHE
-
- 1 Replies
- 1099 Views
-
Last post by NHE
-
- 11 Replies
- 3486 Views
-
Last post by NHE
-
- 1 Replies
- 1631 Views
-
Last post by NHE
-
- 0 Replies
- 3361 Views
-
Last post by NHE
-
- 0 Replies
- 1552 Views
-
Last post by NHE